The purpose of this study is to characterize the pharmacokinetic (PK) of pevonedistat in participants with severe renal impairment and mild hepatic impairment.

This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzyme...